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Background: Controlled inhibition of kinesin motor proteins is highly desired in the field of 
oncology. Among other interventions, there exists “targeted chemotherapeutic regime/options” 
of selective Eg5 competitive and allosteric inhibitors, inducing cancer cell apoptosis and tumor 
regression with improved safety profiles.
Research question: Though promising, such studies are still under clinical trials, for the 
discovery of efficient and least harmful Eg5 inhibitors. The aim of this research was to bridge 
the computational modeling approach with drug design and therapy of cancer cells.
Methods: A computational model, interfaced with the clinical data of “Eg5 dynamics” and 
“inhibitors” via special functions, is presented in this article. Comparisons are made for the drug 
efficacy, and the threshold values are predicted through numerical simulations.
Results: Results are obtained to depict the dynamics induced by ispinesib, when used as an 
inhibitor of kinesin Eg5, on cancer cell lines.
Keywords: drug efficient model, bipolar spindle, Eg5, cancer, mitotic arrest, Eg5 inhibitors
Introduction
The motor proteins are also termed as the “nano-motors” due to their nanoscale 
functionality and integrity in a sophisticated manner. These motors support the funda-
mental cellular processes and act as nanometer-sized machines, converting chemical 
energy into mechanical work. For the past few years, the fundamental principles and 
mechanisms of molecular motor dynamics have remained a topic of debate in the 
field of nanomedicine.1,2
In recent years, mitotic catastrophe (activated during mitosis) has been employed 
as promising onco-suppressive therapeutic strategy. In current clinical strategies, 
various antimitotic cancer drugs such as vinca alkaloids, taxanes, and epothilone 
derivatives, targeting microtubules during cell division, have proved to be clinically 
most successful anticancer agents in bladder, ovarian, breast, lung, and head malig-
nancies.3 Mitosis is a fundamental cell division process that ensures accurate division 
of sister chromatids to the daughter cells. This vital function, coordinated by mitotic 
spindle made up of microtubules, has emerged as validated chemotherapeutic target. 
Microtubules are dynamic polymers of α/β tubulin dimer where chromosomes attach 
and segregate on mitotic spindle during cell division.4,5 Antimitotic drugs perturb it 
by suppressing MT dynamics, thus ensuing an inappropriate chromosome arrange-
ment. Consequently spindle assembly check points are activated that trigger cancer 
cell death via mitotic arrest.6 Though MT targeting drugs are currently cancer-specific 
with good clinical outcome but devastating side effects, dose limiting toxicities are 
the main challenges associated with them as they hit tubulin which is involved in 
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multiple intracellular processes. Moreover, due to innate or 
acquired resistance, patient relapse is a common condition 
encountered while administering these drugs.3 This has led 
to seek for novel alternative drug targets and to develop new 
generation mitosis-specific agents.
Kinesins spindle motor proteins and the microtubules 
work together and are considered potential therapeutic tar-
get in tumors. Being central in driving bipolar spindle and 
subsequent chromosome separation, they provide a chance 
for the development of specific antimitotic agents that may 
overcome resistance along with better side effects profile. 
Kinesins constitute a super family of .650 known motor 
proteins. These motor proteins move unidirectionally along 
the microtubule to perform exclusive functions and harness 
energy by ATP hydrolysis in all eukaryotic cells.7 The key 
cellular function that they perform within intracellular ter-
rain includes microtubule remodeling, vesicular trafficking, 
mitotic spindle assembly, and chromosome segregation in 
dividing cells.8 The structure of all kinesins consists of a head, 
stalk, and tail domain. Head of kinesins contains 340 amino 
acid motor domain provided with an ATP-binding pocket 
and microtubule-binding interface. Being ATPases, kinesins 
hydrolyze ATP via motor domain to release energy required 
for the movement along MT. The stalk is used for dimerization 
and oligomerization while tail is involved in interaction with 
cargo.9 Each 8-nm-long tubulin dimer of polymer microtubule 
serves as one binding site for translocation of kinesin motor 
domain along microtubule powered by ATP hydrolysis.10
The human kinesins contribute significantly in cancer 
development, progression and drug resistance. High expres-
sion in various malignancies has directed huge amount 
of work toward targeting these motor proteins through 
chemotherapeutic intervention. Abnormal proliferation is 
the fundamental feature of all tumors. Proliferating neo-
plasmic cells strictly follow well-ordered events of cell 
cycle comprising growth S-phase where DNA replication 
takes place followed by mitosis for cell division. Orderly 
progression of cell cycle phases is mediated by checkpoints 
and is stalled under unsatisfied conditions leading to cell 
death. First identified motor protein was Eg5, a member of 
kinesin-5 family involved in the establishment of bipolar 
spindle. Downregulation of this protein results in a defected 
monopolar phenotype. They are involved in interconnection 
of chromosomes with spindle, movement of MY dynamics 
and spindle length maintenance.
eg5: an explicit mitotic kinesin motor
Eg5, also known as kinesin spindle protein, KIF11, or Kine-
sin-5, is the simplest yet key player of the mitotic apparatus. 
Eg5, a human gene product encoded by KIF11 gene located 
at 10q24.1, is of particular interest because of its potential 
as a target for therapeutic intervention.11 In humans it is 
expressed in bone marrow, thymus, testis, and tonsils while 
is absent in adult post-mitotic central nervous system.12 It is 
a homotetrameric plus end directed N-terminal microtubule-
based motor protein with a catalytic motor/ATPase domain 
to interact with ATP and microtubules to modulate the 
dynamics and organization of MT arrays. It can cross-link 
and slide antiparallel MTs to congregate mitotic spindle 
while it resides along parallel MT at both poles (Figure 1). A 
defective spindle hampers normal chromosomal segregation 
leading to mitotic arrest via check point protein activation.13 
Metaphase spindle equator comprises antiparallel overlapped 
MTs, while microtubules with parallel orientation dominate 
near spindle poles. During bipolar spindle fabrication, Eg5 
slides apart antiparallel microtubule filaments by pacing 
toward plus ends of each microtubule. It generates outward 
pushing force on centrosomes via cross-linking antiparallel 
microtubules to slide them away from each other. Eg5 inhibi-
tion arrests cells in mitosis with unseparated centrosomes, 
thus suppressing bipolar spindle production. It is found 
that Eg5 may also act as molecular brakes and restrict the 
movement of overlapping antiparallel filaments. Elongated 
anaphase spindle has been reported in the case of loss of Eg5 
activity during cell division.14 Nevertheless, the magnitude 
of these braking force has not been directly calculated, and 
scaling of these forces with respect to relative velocity, 
orientation or overlap is unclear yet. Bipolar architecture 
of mitotic spindle is critical for proper segregation of chro-
mosomes in daughter cells. The work of Shimamoto et al15 
provides a conceptual framework toward mitotic apparatus 
complexity and an insight into self-organization of mitotic 
spindle. After probing feedback mechanism between Eg5 
function and microtubule architecture (velocity and geom-
etry) through experimentations, Shimamoto et al15 suggested 
that spindle assembly can regulate force generation for 
self-organization. The forces generated by Eg5 ensembles 
scale linearly with respect to motor number and length of 
microtubule overlap. They proposed that Eg5 ensembles 
can operate as a “force converter,” decoding microtubule 
regular features such as orientation and overlap length into 
a distinct force signature. Equator of metaphase spindle is a 
dynamic region where antiparallel microtubules keep gliding 
unceasingly at a speed of 23 mm/min (30–50 nm/s) while 
their minus ends are directed toward opposite spindle poles. 
This dynamic antiparallel setup ensembles of Eg5 generate 
either pushing or mechanical resistance, magnitude of that 
is directly proportional to MT sliding velocity, different 
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from unloaded state, and length of overlaid microtubule. 
A linear integration of force output is attained by plus end 
movement of Eg5 ensembles in antiparallel geometry while 
stochastic force output is produced by Eg5 stepping across 
parallel filaments.15
Eg5 is assumed to be a promising therapeutic target as 
it is overexpressed in actively proliferating solid tumors in 
pancreatic, lung, bladder, ovarian, and breast cancers.11,16 
Elevated levels of Eg5 are considered tumorous as overex-
pression results in blast crisis chronic myeloid leukemia, 
activation in mouse B-cell leukemia, and triggering of 
genomic instability in transgenic mice.17,18 Its oncogenic 
potential is further verified by the observation that it elicits 
anti-proliferation of all-trans-retinoic acid in pancreatic can-
cer cell lines.19 Experimental data reveal that Eg5 promotes 
active cancer cell proliferation, colonization, and tumorigen-
esis in pancreatic malignancy in mice. It was found that Eg5 
overexpression affected spindle morphology and resulted 
in multipolar spindle formation. Moreover, a significant 
increase in multinucleate interphase cell population was 
observed, resulting in the accumulation of polyploid cells, 
a condition strongly linked with genomic instability leading 
to cancer. Recent studies have shown that kinesin-5 also 
contributes in evolution of cancer toward metastases via 
spindle length scaling.20 Studies of many cancer cell lines 
along with in vivo human xenograft models have shown 
that Eg5 inhibition ceases bipolar mitotic spindle mor-
phogenesis and ends up in loss-of-function phenotype as a 
monopolar spindle monoester with chromosome distribution 
in rosette-like configuration. This mitotic spindle disaster 
activates checkpoint proteins and induces mitotic arrest and 
subsequent apoptosis of cancer cell.21,22
Upregulation of Eg5, a potent biomarker in various 
malignancies, needs to be targeted for timely and efficacious 
treatment. In contrast to traditional antimitotic drugs targeting 
MT in actively proliferating as well as normal cells, severe 
side effects are not expected from Eg5 inhibitors for being 
target-specific for mitotically active cells. Small-molecule 
inhibitors targeting Eg5 signify a new generation target-spe-
cific anti-cancer agents that are currently undergoing Phase I 
and Phase II clinical trials.23 Mitotic arrest has been induced 
by these inhibitors by obstructing Eg5-dependent MT motil-
ity resulting in aberrant monoastral form. The first reported 
potent Eg5 inhibitor was monastrol that caused mitotic arrest 
without interfering with MT dynamics. Afterwards many 
other allosteric inhibitors have been reported, belonging to 
different chemical classes such as quinazoline, imidazoles, 
thiadiazoles, carbolines, dihydropyrazoles, isoquinolines, 
and benzimidazoles.
In silico biology for representing 
stochastic intracellular changes
Stochastic description of intracellular changes is well-
demonstrated in computational systems biology. However, 
several models are usually generalization of the actual phe-
nomena and the corresponding parameters may be imprecise. 
Figure 1 The positioning of eg5 in a cell before cell division.
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In such cases, the numerical tools can help to investigate the 
analysis results and their level of sensitivity corresponding 
to the parametric perturbations. In this paper, a stochastic 
simulation algorithm is adopted to analyze the variation in 
dynamics of the kinesin motor proteins in three cases (nor-
mal, cancerous, and drug-treated cells). We aim to provide 
the reader a simple yet dynamic model to demonstrate the 
self-organization of stochastic time stepping of the kinesin 
motor proteins under aforementioned conditions.
Problem statement
The study of motor proteins and microtubules is a rich field 
of research with a long list of open problems. Different 
approaches are available in the recent literature to model the 
stochastic transport, mitotic spindle dynamics in cancerous 
cells, and the self-organization of subcellular structures, 
the receptor trafficking, protein–DNA interactions, nuclear 
transport, membrane diffusion, and virus trafficking. This 
motivates us to study and compare change in dynamics of 
Eg5 motor proteins in normal and highly proliferating cancer-
ous cells in addition to change exhibited by diseased cells in 
the presence of obstacles and transient traps, ie, inhibitors. 
In normal cells, metaphase spindle is a highly dynamic entity. 
Being made up of microtubules and associated kinesin motor 
proteins, it experiences huge fluctuations and directed fluxes 
in both physical and chemical processes. However, average 
number, position, and functions of all spindle constituents 
remain steady over time by virtue of its ability to correct tran-
sient changes. In cancerous cells, firmness of this steady-state 
is disturbed, and it experiences huge physical and chemical 
perturbations with evident incapability to recover or to correct 
transient fluctuations in morphology and position. Conse-
quently an aggressive, unchecked mitotic division takes place 
leading to high proliferation rate of tumor cells.
This entire process is really rapid, and the laboratory 
experiments alone are not enough to capture the rapid altera-
tions caused by randomness. The literature provides an evi-
dence that the computational biology (in silico research) has 
always served successfully to model the inter and intracellular 
dynamics of malignant cells.24 This motivates us to use a com-
putational model with some advanced conditions, in order to 
demonstrate the “Eg5 motor proteins based malignant cell’s 
intra-dynamics.” The research methodology encompasses the 
stochastic behavior of Eg5 proteins and its response to both 
the tumor disorders (proliferations) and the drug therapy. 
In this article, after careful analysis of the clinical trials, we 
have selected a special type of inhibitor “Ispinesib ()” which 
is believed to control the overexpression of the motor protein 
Eg520,23,25 in tumor cells. After the selection, we have extended 
the stochastic model available in the literature26–28 inline to 
the given biological problem. We have considered the Hill 
function formalism to demonstrate the addition of drug in the 
model as a reflection of its role in the laboratory-generated 
experiments.25 In this article, we have emphasized on the fact 
that the stochastic modeling of the dynamical behavior of 
motor proteins can help predict the outcomes of cancer drug 
therapy. The inhibition of Eg5 motor protein, a key mitotic 
kinesin motor protein involved in aggressive mitotic activity 
of cancerous cells, is targeted in this study to elaborate this 
statement. We have presented some results based on the math-
ematical model and the parametric values to demonstrate the 
efficiency of the computational tool to make important predic-
tions. This will help improve the ongoing clinical trials on the 
control of Eg5 via inhibitors29,30 in cancerous cells.
Kolmogorov backward equation
The kinesin motor proteins are involved in the mitotic cell 
division. The modeling and simulation of kinesin dynamics 
and their mobility along the microtubules is really challeng-
ing in a normal (case 1), tumor (case 2), and treated cell 
(case 3). Several factors are involved, such as a variation in 
the frequency of the release of the proteins hence change in 
force and motion produced via catalysis in three different 
cases, there can be various time scales in operation, and the 
entire process is inherently stochastic. The Markov process 
(which is also famous as “Chemical Master Equation (CME)” 
framework) is appropriate to conduct such an analysis.
For the clear understanding of the molecular motor pro-
tein dynamics, in this article, a discrete approach is adopted 
and a stochastic model is considered. The probability of the 
molecule in a certain ith state at a time t can help to demon-
strate the dynamics, provided that the backward Kolmogorov 
equation governs its transient dynamics.
Let X
t
 represent an It̂o diffusion in Rn, having generator 
A. Choosing a function h C Rn∈
0
2 ( ) and taking τ=t in Dynkin’s 
formula, we have
 
ν( , ) [ ( )]t x E h Xx
t
=
 
(1)
It is obvious that ν(t, x) is differentiable with respect to 
t and
 
∂
∂
=ν
t
E Ah Xx
t
[ ( )]
 
(2)
In the above equation, Ex[Ah(X
t
)] can be expressed in 
terms of ν.
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Setting and definitions
Taking into account an n-dimensional stochastic differential 
equation
 
dX X dt X dW t X X= + =( ) ( ) ( ), ( )ζ 0
0  
(3)
Let E be the space that may be specified as either E=Rn or 
the torus E=Tn. In above equation, X
0
∈E is the initial condi-
tion (for simplicity, we assume deterministic), and W(t) is 
a standard d-dimensional Weiner process. Both the maps 
ϱ:E→E and ζ:E→Ed are considered to be smooth. Sometimes, 
we preferably use the vector notation for the matrix ζ(x), as 
ζ ζ ζ ζ( ) ( ( ), ( ), , ( ))x x xd= 1 2x     where each of ζi∈E
Consider a discrete numerical approximation of Equation 3 
given as follows
 
X X
i i i+ =1 Φ κ,ν( , ),  (4)
where X
i
∈E, ∀i ≥ 0  and Φ(., κ, ν
i
):E→E is the discrete 
numerical flow, κ stands for the time-step size and ν
i
 repre-
sents a random vector.
In vivo and in vitro studies and the 
theoretical model
In this section, we discuss some of the experimental studies 
and interface with our theoretical model.
Data-based stochastic effects of eg5 
inhibitors
Tumor cells and eg5 data
Oncogenic role of Eg5 has been established by a large body 
of experiments, and it is identified as a potent prognostic 
biomarker in various malignancies. Lu et al31 investigated 
the correlation between upregulated expressions of Eg5 and 
clinicopathological characteristics in laryngeal squamous 
cell carcinoma (LSCC) patients. For that purpose immuno-
histochemistry (IHC) analysis in 137 LSCC cases along with 
one-step qPCR test with 20 fresh-frozen LSCC samples was 
done. Significant higher Eg5 protein level in comparison 
with corresponding non-cancerous tissues were correlated 
with lymph node metastasis and TNM stage, independent 
factors to envisage critical prognosis for LSCC patients.31 
Similarly correlation between clinicopathological character-
istics and Eg5 expression in non-muscle invasive urothelial 
carcinoma was investigated by analyzing large number of 
IHC specimens including grade: G1, 32 cases; G2, 92 cases; 
and G3, 39 cases; Stage: pTa, 49 cases and pT1, 114 cases. 
A total of 163 non-muscle invasive cases were analyzed 
via survival analysis to find out the prognostic significance 
of Eg5 immunoreactivity. A strong imperative connection 
between Eg5 overexpression and tumor grade (P=0.006) and 
tumor stage (P=0.057) was discovered. It was concluded 
that Eg5 overexpression signifies a self-regulating prog-
nostic factor in envisaging initial intravesical recurrence in 
non-muscle invasive bladder cancer patients.16 Sun et al32 
evaluated the prognostic significance of Eg5 upregulation 
in renal cell carcinoma (RCC) patients via IHC and cor-
related clinicopathological parameters using the univariate 
and multivariate analyses of 164 patients and 164 tissue 
specimens, regularly followed from 5 to 80 months. They 
suggested that Eg5 may serve as a prognostic factor for renal 
cancer prediction, evolution, and appropriate treatments. 
Experimental data indicated a significant relation between 
tumor nuclear grade (P=0.019), stage (P=0.007), and size 
(P=0.033) with Eg5 expression for recurrence-free RCC 
patient survival.32 Eg5 expression has also been associated 
with occurrence and rapid metastasizing ability of pancreatic 
cancer. In pancreas cancer cell lines, high expression of Eg5 
promotes tumorigenesis by boosting cell proliferation in an 
ATPase activity-dependent manner. It stimulates multipolar 
spindle formation and consequent multi-nucleation leading 
to polyploid cell production. It was discovered that high 
expression of Eg5 encourages anchorage independent cell 
growth and tumor metastases in mice model.11
eg5 data after inhibition
Due to close association of Eg5 with tumorigenesis, metas-
tasis, and tumor drug resistance, Eg5/KSP has emerged as a 
promising target for anticancer therapeutic agents, and vari-
ous KSP inhibitors are under clinical trials as monotherapy 
or adjuvant therapy candidate. Eg5 inhibitors cause cell 
cycle arrest during mitosis by targeting KSP via contrasting 
mechanisms. ATP-uncompetitive inhibitors bind near loop 
L5 to stabilize the bound nucleotide and trap the motor in a 
weak binding state. Some potent inhibitors of this category 
exhibiting clinical efficacy include monastrol, filanesib, 
litronesib, K858, S-trityl-l-cysteine (STLC), and ispinesib 
()25,33–35 (in Figure 2, the kinesin-5 inhibitor complex is pre-
sented). Whereas thiazole FCPT act as an ATP competitive 
inhibitor and bind directly to the nucleotide binding active 
site.36 Some biaryl inhibitors such as PVZB1194 and GSK-
133 act as allosteric competitive inhibitors of ATP binding 
and bind near the α4–α6 interface.35,37 BRD9876 is a similar 
type of ATP non-competitive inhibitor that preferentially 
bind to microtubule bound Eg5.38 These inhibitors may act 
as a chemical probe to understand and modulate the Eg5 
activity within a cell.
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Detailed analysis depicted different distinct effects of 
aforementioned inhibitors on MT stability and spindle integ-
rity. L5 inhibitors obliterate Eg5 microtubule stabilizing abil-
ity causing metaphase spindle down fall in contrast to rigor 
inhibitor BRD9876 that stabilizes microtubule and hence 
metaphase spindle by suppressing MT depolymerization.
computational model interfaced with 
real data
In the recent literature,40 the motor proteins and their associ-
ated stochastic dynamics are studied extensively due to their 
crucial role, especially in mitotic cell division. These motor 
proteins are mostly believed to obey periodic motion. Such 
a motion usually takes place along the potential, which actu-
ally describes the distinct biochemical states of the motor. 
There are several types of motor proteins involved in mitosis 
process in human cell. Among these, EG5 motor proteins play 
a dominant role in the cancer invasion. It has been verified 
through laboratory generated experiments, (as reported by 
Wakui et al25) that EG5 is overexpressed in malignant cells. 
We have focused on the dynamics of this special type of 
motor proteins using a theoretical model (that is explained 
in detail in “Kolmogorov backward equation” and “Setting 
and definitions” sections), where ν(x, t) represents the prob-
ability (or more precisely the probability density) for EG5 to 
be found at location x at time t. The conditions to solve the 
Kolmogorov backward equation were considered to be peri-
odic. Since at the micro level, the probability density function 
can be written as a function of mean square displacement, 
therefore as the mean square displacement of EG5 proteins 
changed, we obtained a variation in the conditions interfaced 
in the numerical solver. This can be elaborated with the aid 
of the probability density function
 
ν=
−





−




∫∫
e
e dxdp
k T
k T
px
B
B


 
(5)
where p is the momentum of the motor protein (depending on 
the rate of change of the displacement), ב is the sum of kinetic 
and potential energies (as a function of displacement), k
B
 is 
the Boltzmann constant and T is the absolute temperature. 
In this article, the parametric values were adapted from the 
data presented by Chen et al.41
Another important feature of this study is that the drug 
therapy is synchronized in the model through the Hill’s func-
tion formulation.42 The EG5 molecules were considered as 
the enzymatic receptors and the drug molecules were con-
sidered as the inhibiting ligands. The simple manipulation 
of the chemical equations leads to an important formula, 
which is used extensively in the literature,43 but for the very 
first time has been synchronized with the sinusoidal drift 
(ϱ in Equation 3) of the Kolmogorov backward equation. 
The Hill function for our model is derived using the follow-
ing formalism:
Hill functions
The reaction, in which g ligand molecules I
sp
 bind the receptor 
Eg5, is given as follows:
 
Eg gI Eg
sp gIsp
5 5+ 
 
(6)
$'3
/
.LQHVLQ$'3,VSLQHVLE
,VSLQHVLE
α
α
,VSLQHVLE
$
2
1
1
12
&O
1+
,VSLQHVLE
%
Figure 2 Kinesin-5 complex ([A] adapted from Park et al39) for the preparation of (B) Ispinesib antitumor drug.
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In case of chemical equilibrium, the following relation 
is satisfied
 
[ ] [ ] [ ]Eg I R Eg
sp
g
Eg glsp
5 5
5
+ =
 
(7)
In the above equation, K represents the reaction dissocia-
tion constant and [Eg5] and [I
sp
] stand for the concentration of 
the chemical species Eg5 and I
sp
, respectively. If we consider 
a constant number of receptors,
 
[ ] [ ] [ ]Eg Eg Eg
gI Totsp
5 5 5+ =
 
(8)
Equations 6 and 7 then lead to the following fractions:
 
H I
Eg
Eg
I
K I
H I
sp
gI
Tot
sp
g
g
sp
g
sp
sp( )
( )
([ ])
[ ]
[ ]
[ ]
[ ]
([
1
2
5
5
= =
+
 and
])
[ ]
[ ] [ ]
= =
+
Eg
Eg
K
K I
Tot
g
g
sp
g
5
5
 
(9)
where both H(1) and H(2) are known as Hill functions, rep-
resenting the fraction of occupied and free molecules Eg5 
respectively, with Kg=R
Eg5
. Now let us define x=[I
sp
]/K, then 
the normalized Hill function is stated as
 
h x H Kx
x
x
h x H Kx
x
g
g
g
( ) ( )
( ) ( )
( ) ( )
( ) ( )
1 1
2 2
1
1
1
= =
+
= =
+
and
 
(10)
This non-dimensional entity h(1)(x) when incorporated 
with the sinusoidal drift (ϱ in Equation 3) of the Kolmogorov 
backward equation works as a useful tool to trace the effect 
of the drug inhibitors on the Eg5 enzymes. This impact is 
demonstrated with the aid of graphical interpretation in 
Figure 3.
We have solved the Kolmogorov backward equation to 
understand the three cases, kinesin motor proteins dynam-
ics in normal cell, tumor cell, and treated cell. Each case 
was differentiated from the other case, based on the initial 
dynamics (interfaced in the numerical computations). 
Figure 3 Drug therapy – theoretical strategy and the impact on drift.








    ;
+LJKHUGRVHRI,VS
'ULI
W
    








    
/RZHUGRVHRI,VS
'ULI
W
    ;
,QLWLDOGULIW 6LJPRLGDORFFXSDQF\RI(J 1HWGULIW
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
87
.1
.1
67
 o
n 
19
-O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6436
sherin et al
The finite element algorithm was applied, and the mass and 
stiffness matrices were obtained. The matrix exponential 
is computed using a scaling and squaring algorithm with a 
Pade approximation.
Results and discussion
Mathematical modeling of the stochastic intracellular pertur-
bations in the expression and function of Eg5 in malignancy 
and on inhibition may prove to be fruitful in understanding 
the current challenges of cellular scale studies. In this model, 
an elevated expression of Eg5 generates excess mechanical 
forces for the movement of anti-parallel microtubules and 
perturbs the balance of forces normally required for bipo-
lar spindle formation, thereby inducing multipolar spindle 
assembly and impairing chromosome segregation. The cells 
may undergo mitotic slippage due to the inability to correct 
errors and satisfy the spindle assembly checkpoint, result-
ing in cytokinesis arrest and abnormal proliferation. These 
events in turn lead to genomic instability and ultimately 
tumorigenesis. This model displays the aggressive stochastic 
behavior of kinesin-5 in cancerous cells and tamed behavior 
upon inhibition. To demonstrate this behavior, in this section, 
we have presented some results based on the experimental 
findings and numerical simulations.
Figures 4 and 5 depict the probability density function 
for the motor proteins in a normal cell and in a cell with 
malignancy. We can see that the shape changes from regular 
soliton-like structure to frequent humps.
From Figures 6 and 7 it is obvious that for lower values 
of g (that controls the drug concentration in our model), there 
is a decline in amplitude of the pathway and for increased 
values (as shown in Figure 8) it reduces asymptotically, the 
straight line after x=12 in Figure 8 shows apoptosis, that is, 
no motion of the motor protein.
Conclusion
Different therapeutics have been designed to date to control 
the rapid proliferation of cancerous cells. These includes the 
cytotoxic antimitotic treatments, of which antitubulin com-
pounds have received remarkable attention; however, such 
treatments are responsible for dose-limiting side effects. This 
has led the oncologists and biochemical engineers to design 
new mechanisms of action to reduce such “chemoresistance.” 
Mitosis-specific kinesin “Eg5,” which is a fundamental in 
mitotic progression, is considered as a target for designing 
such new anticancer agents.37,44 The recent clinical trials have 
proved that the kinesin Eg5 inhibitors have antiproliferative 
effect and induced apoptosis. Therefore, motivated by the 
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Figure 4 The probability density function for the motor proteins in a normal cell.
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Figure 5 The probability density function for the motor proteins in a tumor cell when no drug was injected.
stochastic nature of the process,45,46 we analyzed the effects 
induced by ispinesib, which is an inhibitor of kinesin Eg5, 
on cancer cell lines, with the aid of a theoretical model. The 
mathematical model is physically motivated by the existing 
models as well as the laboratory outcomes (depicted from 
the work of Chen et al41 specifically for ispinesib) and thus 
presents the dynamics to a better accuracy.
It is worth mentioning that no single drug designed for 
the Eg5 inhibition has progressed beyond clinical trials to 
date.47 Evidence is available in the literature, supporting 
the fact that different inhibitors target Eg5 differently,48 in 
normal, aberrant, and degenerative manner; furthermore, 
novel drug development strategies are under clinical 
trials.49,50 Chen et al41 investigated the effects of inhibitors 
on Eg5-mediated stabilization of dynamic microtubules 
and concluded that different Eg5 inhibitors inhibit spindle 
formation through contrasting mechanisms. Our future 
research will focus on the theoretical investigation of the 
Pathway relative to time at g = 1
25
0
0.5
0
1
0.5
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Figure 6 states of motor protein inside a cancerous cell for lower dose of drug.
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Figure 8 states of motor protein of a treated cell, for enhanced drug dose; the straight line refers to no movement (ie, apoptosis).
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Figure 7 states of motor protein inside a cancerous cell for increased dose of drug.
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contrasting effects of a group of inhibitors on Eg5 motor 
proteins.
In short, nanomotors are not always “the same but 
smaller.” Instead, sometimes “small is different” (Uzi 
Landman) applies, which creates opportunities to target 
their functionality for treatment and medication. Therefore, 
the sheer availability of data obtained from the clinical 
trials of “inhibition processes” of the nano-sized motor 
proteins is a great opportunity that calls for theoretical 
exploration.
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